Press Releases - 2022-06-08

Date	Title	Company
08-Jun-2022	Diurnal to present research into new treatments of Congenital Adrenal Hyperplasia (CAH) at ENDO 2022	Diurnal Group plc
08-Jun-2022	Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth	Sanofi
08-Jun-2022	CatSci Launch SmartPath - An Innovative Digital API Risk Assessment	CatSci Ltd
08-Jun-2022	Herpes Labialis Treatment Market is anticipated to expand at a CAGR of 4.7% over forecast period 2022-2028	MARKITWIRED
08-Jun-2022	Anti-Osteoporosis Therapy and Fracture Healing Market to record a CAGR of 3% through 2030	MARKITWIRED
08-Jun-2022	Cervical Pillows Market is projected to register a CAGR of 4.5% in terms of value during the forecast period 2022–2028	MARKITWIRED
08-Jun-2022	Single-Photon Emission Computed Tomography Market Competitive Growth Strategies Based on Type, Applications, End User and Region	MARKITWIRED
08-Jun-2022	Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium	Businesswire
08-Jun-2022	Swine Respiratory Diseases Treatment Market size reaching a value of over US$ 1,100 Million in 2027	MARKITWIRED
08-Jun-2022	Lead Pharma and Oxeltis receive €800K EUREKA Eurostars grant	Andrew Lloyd Associates
08-Jun-2022	FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older	Novavax
08-Jun-2022	Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial	AstraZeneca
08-Jun-2022	Douglas GmbH: DOUGLAS commits to a more sustainable beauty industry – clean beauty, diversity and climate protection as top priorities	Douglas GmbH
08-Jun-2022	University of Manchester Adds Carterra’s LSA® Instrument for High-Throughput Antibody Screening and Characterization	Businesswire
08-Jun-2022	ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions Announce a New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2	ProteoGenix
08-Jun-2022	Nosopharm and GNA Now announce positive results for the late preclinical development of the first-in-class antibiotic NOSO-502	Andrew Lloyd Associates
08-Jun-2022	Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001	Relief Therapeutics Holding SA
08-Jun-2022	Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022	Vivoryon Therapeutics N.V.
08-Jun-2022	EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer	Businesswire